Real-world survival outcomes to first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancer

Author:

Panagiotou Emmanouil1,Vathiotis Ioannis A.1,Montgomery Austin2,Moeckel Camille2,Livanou Maria Effrosyni1,Mastrogeorgiou Michail1,Evangelou Georgios1,Charpidou Andriani1,Mouratidis Ioannis2,Georgakopoulos-Soares Ilias2,Syrigos Nikolaos K.1

Affiliation:

1. Sotiria General Hospital for Chest Diseases

2. The Pennsylvania State University College of Medicine

Abstract

Abstract Background Recent approval of programmed death-ligand 1 (PD-L1) inhibitors in the first line of treatment has transformed the therapeutic landscape of extensive-stage small cell lung cancer (ES-SCLC); real-world (rw) evidence of efficacy is currently limited. Patients and Methods: We retrospectively assessed patients with SCLC, large cell neuroendocrine carcinoma (LCNEC) or combined histology receiving chemoimmunotherapy in the first-line treatment setting at “Sotiria” General Hospital for Chest Diseases, Athens, Greece. Patient demographics and disease characteristics were extracted using a standardized form. Kaplan-Meier curves were used to calculate rw progression-free survival (rwPFS) and rw overall survival (rwOS). Cox proportional hazards regression analysis was utilized to identify associations between patient characteristics and outcome. Results One hundred patients were included in the analysis. Median rwPFS was 7.2 months (95% CI, 6.7–12.0 months) and median rwOS was 14.4 months (95% CI, 9.4–18.6 months); efficacy metrics were similar between patients treated with durvalumab and atezolizumab. In the multivariate analysis, the number of metastatic sites was associated with increased risk of death (HR, 1.47; 95% CI, 1.11–1.94; p = 0.007), while BMI was associated with decreased risk (HR, 0.89; 95% CI, 0.81–0.97; p = 0.008). Exploratory biomarker analysis revealed a correlation between different prognostic scores (RMH, GRIM, LIPI, and EPSILoN) and rwOS. Conclusion Real-world data confirm the efficacy of first-line chemoimmunotherapy in patients with ES-SCLC. The association between prognostic scores and survival outcomes in ES-SCLC should be explored in prospective studies.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3